



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

CONTACT:

Sharon L. Weinstein
Director, Investor Relations
& Corporate Communications
240 632 5511
sweinstein@genvec.com

GENVEC TO DEVELOP NEW MALARIA VACCINE FOR THE U.S MILITARY

GAITHERSBURG, MD – September 10, 2007 – GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a collaborative research and development agreement (CRADA) with the U.S. Military Malaria Vaccine Program at the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC) for the development and pre-clinical testing of a malaria vaccine candidate against *Plasmodium vivax* (*P. vivax*). More than 50 percent of malaria cases in US military personnel are caused by *P. vivax*, which is debilitating upon primary infection and can cause recurrent illness years after infection occurs. This malaria strain has a significant negative impact on world economic productivity and is a major threat to military preparedness.

In addition to the CRADA, GenVec has signed a one-year contract with the Department of Defense to construct and test the adenovector-based vaccine, which carries a novel proprietary antigen against *P. vivax* developed by WRAIR scientists. GenVec and its collaborators will jointly design pre-clinical studies to evaluate the immunogenicity of the adenovector and WRAIR's recombinant sub-unit vaccine in various combination prime/boost vaccination strategies.

- more -

“We are very pleased to enter this new collaboration with two of the world’s leading malaria vaccine development institutions,” stated C. Richter King, Ph.D., GenVec’s Senior Vice President of Research. “GenVec has a well-established, successful collaboration with the NMRC for the development of vaccines against *P. falciparum*, the most deadly malaria species. Their continued enthusiastic support highlights the utility of our adenovector technology platform for the generation of novel vaccines against poorly treated diseases.”

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec’s product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec’s proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec’s business, financial conditions and results of operations, are contained in GenVec’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.